| 2010年2月9日 (星期二) |
| 22:03 | Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement (PrimeZone Media Network) |
| 2010年2月8日 (星期一) |
| 22:15 | Nabi Biopharmaceuticals Completes Another PentaStaph(TM) Milestone (PrimeZone Media Network) |
| 2010年1月6日 (星期三) |
| 21:21 | Coverage initiated on NABI Biopharma by C.K. Cooper (Briefing.com) |
| 2009年12月16日 (星期三) |
| 03:35 | 4-Star Stocks on the Upswing (at Motley Fool) |
| 2009年12月9日 (星期三) |
| 22:25 | Nabi Biopharmaceuticals to Receive $5 Million Milestone Payment From GlaxoSmithKline Biologicals (PrimeZone Media Network) |
| 2009年11月26日 (星期四) |
| 05:21 | NABI BIOPHARMACEUTICALS Files SEC form 8-K, Change in Directors or Principal Officers (EDGAR Online) |
| 2009年11月18日 (星期三) |
| 02:35 | This Partnership Is Smoking! (at Motley Fool) |
| 00:00 | Nabi Biopharmaceuticals Conference Call to discuss announcement of the exclusive worldwide option and licensing agreement for NicVAX(R) scheduled for 11:00 am ET today (CCBN) |
| 2009年11月17日 (星期二) |
| 20:55 | Glaxo and Nabi Team Up for Nicotine Vaccine () |
| 11:38 | [$$] Sonic Solutions, Nabi and Bristow Advance (at The Wall Street Journal Online) |
| 06:26 | NABI BIOPHARMACEUTICALS Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fi (EDGAR Online) |
| 02:05 | Nabi soars on Glaxo deal for smoking vaccine (bizjournals.com) |
| 2009年11月16日 (星期一) |
| 22:04 | Sprint, CombinatoRx: Early Volume Plays (at TheStreet.com) |
| 21:30 | Nabi Biopharmaceuticals to Hold Conference Call (PrimeZone Media Network) |
| 20:56 | GlaxoSmithKline, Nabi to develop smoking vaccine (AP) |
| 19:15 | Nabi, Glaxo agree nicotine vaccine licensing deal (at MarketWatch) |
| 19:00 | GSK and Nabi Announce Agreement for NicVAX(R), a Vaccine for Nicotine Addiction (PrimeZone Media Network) |
| 2009年11月11日 (星期三) |
| 22:05 | NABI BIOPHARMACEUTICALS Financials (EDGAR Online Financials) |
| 2009年11月6日 (星期五) |
| 05:30 | Nabi Biopharmaceuticals Earnings Call scheduled for 4:30 pm ET today (CCBN) |
| 05:18 | NABI BIOPHARMACEUTICALS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (EDGAR Online) |
0.04 (0.82%)
